Loratadine and Ceftazidime drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Loratadine (loratadine) and Ceftazidime (ceftazidime). Common drug interactions include cough among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Loratadine and Ceftazidime. It is created by eHealthMe based on reports of 76 people who take the same drugs from the FDA, and is updated regularly.

What is Loratadine?

Loratadine has active ingredients of loratadine. It is often used in allergies. eHealthMe is studying from 56,314 Loratadine users. Check the latest studies of Loratadine.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

On Jul, 15, 2026

76 people who take Loratadine and Ceftazidime together, and have interactions are studied.

Loratadine and Ceftazidime drug interactions.

What are the common drug interactions of Loratadine and Ceftazidime, by gender? *:

female:

Cough
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Depression
Device failure
Dry mouth
Emotional distress
Fall
Fatigue (feeling of tiredness)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)

male:

Pneumonia
Adverse reaction
Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
Epistaxis (bleed from the nose)
Lip haemorrhage (bleeding lip)
Respiratory distress (difficulty in breathing)
Stomatitis (inflammation of mucous membrane of mouth)
Haemorrhage (bleeding)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Wound infection bacterial

What are the common drug interactions of Loratadine and Ceftazidime, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Adenovirus infection
Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
Epistaxis (bleed from the nose)
Lip haemorrhage (bleeding lip)
Respiratory distress (difficulty in breathing)
Stomatitis (inflammation of mucous membrane of mouth)
Device dislocation
Umbilical hernia (an outward bulging (protrusion) of the abdominal lining or part of the abdominal organ(s) through the area around the belly button)
Weight gain poor
Abdominal pain

10-19:

Abdominal distension
Abdominal pain
Pulmonary veno-occlusive disease (obstructive disease of the pulmonary veins)
Erythema (redness of the skin)
Hypersensitivity
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Lip blister
Lip swelling
Malaise (a feeling of general discomfort or uneasiness)
Pruritus (severe itching of the skin)

20-29:

Decreased appetite
Lung disorder (lung disease)
Nausea (feeling of having an urge to vomit)
Pharyngitis (inflammation of the pharynx, causing a sore throat)

30-39:

Abdominal pain upper
Anxiety
Asthma
Constipation
Dysphonia (speech disorder attributable to a disorder of phonation)
Haemoglobin decreased
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Insomnia (sleeplessness)
Leukocytosis (increased white blood cells)
Nausea (feeling of having an urge to vomit)

40-49:

Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Renal failure (kidney dysfunction)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Bone density decreased
Cardiac arrest
Chronic kidney disease
Depression
Emotional distress
Pain

50-59:

Hypoaesthesia (reduced sense of touch or sensation)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Ingrown hair
Injury
Intervertebral disc degeneration (spinal disc degeneration)
Intervertebral disc protrusion (spinal disc protrusion)
Joint injury
Keratoconjunctivitis sicca (inflammation of the conjunctiva and cornea of the eye with decreased tears)
Lacrimation increased
Lower respiratory tract infection

60+:

Pneumonia
Adverse reaction
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Wound infection bacterial
Vertigo
Blood culture positive
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Respiratory failure (inadequate gas exchange by the respiratory system)
Chest pain
Dyspnoea (difficult or laboured respiration)

What are the existing conditions these people have? *

Pain: 17 people, 22.37%
Constipation: 16 people, 21.05%
High Blood Pressure: 14 people, 18.42%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 9 people, 11.84%
Pneumonia: 9 people, 11.84%
Stress And Anxiety: 8 people, 10.53%
Insomnia (sleeplessness): 8 people, 10.53%
Cystic Fibrosis (disease of the secretary glands): 7 people, 9.21%
Nausea (feeling of having an urge to vomit): 7 people, 9.21%
Metastases To Bone (cancer spreads to bone): 6 people, 7.89%

* Approximation only. Some reports may have incomplete information.

Do you take Loratadine and Ceftazidime?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously